Trending

#CTCL

Latest posts tagged with #CTCL on Bluesky

Latest Top
Trending

Posts tagged #CTCL

Post image

#SNGX: Positive Results for Phase 2a Trial in Psoriasis buff.ly/gVSMjlb

#biotech #lymphoma #CTCL

0 0 0 0
Preview
Lymphir Now Available for R/R Cutaneous T-Cell Lymphoma - Oncology Nurse Advisor Lymphir is supplied as a 300mcg lyophilized cake in a single-dose vial for reconstitution and further dilution.

Lymphir™ (denileukin diftitox-cxdl) is now available for the treatment of R/R Stage I-III #CTCL after at least 1 prior systemic therapy. From @medicalprofref.bsky.social.

https://bit.ly/48EhSc1

#lymsm

0 0 0 0
Preview
Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment Soligenix has successfully enrolled 50 patients in its HyBryte Phase 3 clinical trial for Cutaneous T-Cell Lymphoma, paving the way for a critical interim analysis in 2026.

Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment #USA #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials Soligenix, Inc. outlines its recent milestones and third quarter financial results for 2025, focusing on clinical trials and future strategies.

Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification Key PointsThere is poor survival in advanced stage MF/SS.CLIPI stratifies patients with advanced MF/SS into risk groups for survival and has been validated

Now it is imperative to include CLIPI in the routine evaluation of advanced stages Mycosis Fungoides & Sézary syndrome; especially when considering for alloSCT #ctcl

ashpublications.org/blood/articl...

1 0 0 0
Preview
Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma Soligenix has reached a significant safety milestone in their Phase 3 trial for HyBryte™, aimed at treating cutaneous T-cell lymphoma, confirming its acceptable safety profile.

Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement Soligenix, Inc. has expanded its European Medical Advisory Board as they move forward with a Phase 3 clinical study for HyBryte™ in treating cutaneous T-cell lymphoma.

Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Rare Diseases and Their Long-Term Revenue Potential: What Innovators Need to Know As the U.S. population ages, chronic and rare diseases become pressing health issues. Innovations in treatment signal a significant revenue opportunity for pharmaceutical companies.

Rare Diseases and Their Long-Term Revenue Potential: What Innovators Need to Know #United_States #New_York #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Dr. Michael Girardi Receives LLS Translational Research Program Award Michael Girardi, MD, FAAD, Evans Professor of Dermatology, has been awarded the 2025 Translational Research Program Award from The Leukemia and Lymphoma Society

Congratulations to Dr. Michael Girardi, recipient of the 2025 Translational Research Program Award from
@llsusa.bsky.social to support his research developing new treatments for T-cell #lymphoma. #CTCL
yalecancercenter.org/news-article...
@yaleschoolofmed.bsky.social

0 0 0 0
Post image

#MycosisFungoides #CTCL
Atypical intraepidermal lymphocytes tagging along the basal epidermis with halos. No spongiosis. This case really doesn’t need immunohistochemisry to confirm #classic 😉
#pathology
#dermpath
#bluepath

6 1 1 0
Preview
Promising Results from HyBryte™ Therapy Show 75% Success Rate in CTCL Patients Recent interim results reveal that 75% of patients with early-stage cutaneous T-cell lymphoma achieved treatment success using HyBryte™ within 18 weeks, showcasing its rapid action and safety.

Promising Results from HyBryte™ Therapy Show 75% Success Rate in CTCL Patients #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Post image

Our recent article shines a light on a rare disease – cutaneous T-cell lymphoma (CTCL). 🩸🔬

📖 Dive into the diagnosis & treatment of this malignancy, featuring insights from leading experts.

👉 buff.ly/sdBGvVG 👈

#CTCL #RareDisease #HemOnc #Lymphoma #LYMsm #CTSM #ImmunoOnc #BloodSky #HemeSky

1 0 0 0
Preview
Soligenix Reports Promising Accomplishments and Financial Insights for 2024 Year-End Soligenix, Inc. shares its latest achievements and financial results for the year ending December 31, 2024, demonstrating significant progress in biopharmaceutical development.

Soligenix Reports Promising Accomplishments and Financial Insights for 2024 Year-End #United_States #Princeton #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab - PubMed MAVORIC demonstrated greater efficacy with mogamulizumab <i>vs.</i> vorinostat in relapsed/refractory patients with CTCL, including those with more advanced disease. Concomitant steroid use improved O...

The #MAVORIC trial led by Dr. Francine Foss demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with #CTCL, including those with more advanced disease.
pubmed.ncbi.nlm.nih.gov/39894454/
@yale-hematology.bsky.social @yaleschoolofmed.bsky.social

1 1 0 0
Post image

A fusion protein therapy may be an effective treatment option for cutaneous T-cell #lymphoma, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Read more: news.feinberg.northwestern.edu/2025/01/17/i... via @nufeinbergmed.bsky.social #CTCL #lymsm

4 0 0 0
Preview
Exciting Progress in Treatment of Early-Stage Cutaneous T-Cell Lymphoma with HyBryte™ Soligenix, Inc. shares promising interim results from a study on HyBryte™, demonstrating positive outcomes in treating early-stage cutaneous T-cell lymphoma with a safety profile that stands out.

Exciting Progress in Treatment of Early-Stage Cutaneous T-Cell Lymphoma with HyBryte™ #None #Soligenix #CTCL #HyBryte

0 0 0 0
Preview
Soligenix Launches Phase 3 Trial for HyBryte™ to Treat Cutaneous T-Cell Lymphoma Soligenix has initiated a confirmatory Phase 3 trial of HyBryte™, a novel therapy for cutaneous T-cell lymphoma, following previous promising studies.

Soligenix Launches Phase 3 Trial for HyBryte™ to Treat Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte

1 0 0 0

It’s great to see new research on #CTCL. I have the Folliculotropic subtype of mycosis fungoides. Luckily, I have stayed in stage 1A since my diagnosis 3 years ago. But it is a frustrating and uncomfortable cancer. Hopefully this will add much needed data that can be used to develop treatments.

3 0 1 0
Preview
Exciting Updates on HyBryte™: Clinical Study Shows Improved Results After Treatments Recent clinical results for HyBryte™ show remarkable improvements in patients even after treatment cessation, highlighting its efficacy and safety.

Exciting Updates on HyBryte™: Clinical Study Shows Improved Results After Treatments #United_States #HyBryte™_Treatment #Soligenix #CTCL #Princeton,_NJ

0 0 0 0

Making a database using the top 300 colleges and Birmingham-Southern pops up. I'm sad all over again.
#HigherEd #CTCL #EduSky

0 0 0 0

Schöne Nachrichten für #4SC, über die ich "drüben" auf Twitter/X schon geschrieben habe. Orphan Drug für Resminostat von der #EMA bei #CTCL ... Achtung, marktenger #Biotech Small Cap! www.4investors.de/nachrichten/...

0 0 0 0